Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 26

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 26
---
 be issued independently or together with any securities and may be attached to or separate from those securities. The warrants may be issued under warrant or subscription agreements to be entered into between us and a bank or trust company, as warrant agent, all of which will be described in the prospectus supplement relating to the warrants we are offering. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.

The particular terms of the warrants, the warrant or subscription agreements relating to the warrants and the warrant certificates representing the warrants will be described in the applicable prospectus supplement, including, as applicable:

| ● | the title of such warrants; |

| ● | the aggregate number of 
 such warrants;          |

| ● | the price or prices at                            
 which such warrants will be issued and exercised; |

| ● | the currency or currencies                           
 in which the price of such warrants will be payable; |

| ● | the date on which the right                                                             
 to exercise such warrants shall commence and the date on which such right shall expire; |

| ● | if applicable, the minimum                                                 
 or maximum amount of such warrants which may be exercised at any one time; |

| ● | if applicable, the designation                                                                                                  
 and terms of the securities with which such warrants are issued and the number of such warrants issued with each such security; |

| ● | if applicable, the date                                                                      
 on and after which such warrants and the related securities will be separately transferable; |

| ● | if applicable, any provisions          
 for cashless exercise of the warrants; |

| ● | if applicable, any exercise                                                                 
 limitations with respect to the ownership limitations by the holder exercising the warrant; |

| ● | information with respect          
 to book-entry procedures, if any; |

| ● | any material U.K. and United            
 States federal income tax consequences; |

| ● | the anti-dilution provisions 
 of the warrants, if any; and |

| ● | any other terms of such                                                                                       
 warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants. |

Holders of warrants will not be entitled, solely by virtue of being holders, to vote, to consent, to receive dividends, to receive notice as shareholders with respect to any meeting of shareholders for the election of directors or any other matters, or to exercise any rights whatsoever as a holder of the equity securities purchasable upon exercise of the warrants